Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Plasma samples showed an association between suppressed extracellular vesicles and an increased risk for liver cancer.

Over 80% of hepatocellular carcinoma (HCC) – the third-leading cause of cancer deaths globally – emerges from advanced liver fibrosis or cirrhosis. A comprehensive review in Hepatology International ...

More than 500,000 annual liver cancer diagnoses could be prevented with global interventions aimed at reducing viral hepatitis B and C, alcohol consumption and a disease strongly associated with ...

Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Nature featuring groundbreaking preclinical data for the treatment ...

Certain foods and nutrients were found to influence the risk of developing liver cancer. For example, aflatoxins (toxins from ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ...

Japanese drugmaker Eisai revealed that its in-house discovered tyrosine kinase inhibitor, Lenvima (lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial ...

US researchers analyzed national death certificate data to compare trends in hepatocellular carcinoma (HCC)-related mortality and underlying etiologies of chronic liver disease linked to HCC-related ...

STUTTGART, Germany I July 30, 2025 I La Merie Publishing released its newest product entitled: Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis.

A new study has established that the follow-up of the fatty liver index (FLI), both baseline and longitudinally, is an ...

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) ...